Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized dose-comparison study of radium-223 dichloride in castration-resistant prostate cancer with bone metastases
2013-003118-42Phase 2Completed
- Sponsor
- Bayer
- Start
- Jan 2014
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of radium-223 dichloride in castration-resistant prostate cancer (CRPC) and prostate cancer (PCa) (3 arms), sponsored by Bayer. Primary endpoint: Symptomatic skeletal event-free survival. Started Jan 2014; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
castration-resistant prostate cancer (CRPC)prostate cancer (PCa)
Beyond the preview
Go deeper on 2013-003118-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003118-42.